JANSSEN PHARMACEUTICA N .V.;VERTEX PHARMACEUTICALS INCORPORATED
发明人:
BAMBANG S. ADIWIJAYA,GASTON RAFAEL PICCHIO,MARIA GLORIA BEUMONT,RAMON POLO,ROBERT S. KAUFFMAN,STEFAN RIKARD HERDINIUS,VARUN GARG
申请号：
BRPI0915109
公开号：
BRPI0915109A2
申请日:
2009.06.10
申请国别(地区):
BR
年份:
2016
代理人:
摘要：
This invention relates to the use of specific dosing regimens of telaprevir in combination with peg-IFN and RBV in the treatment of HCV patients, wherein the treatment comprises (a) a lead-in phase of administering to the subject pegylated interferon and ribavirin, and (b) a treatment phase of administering to the subject a combination of telaprevir, pegylated interferon and ribavirin.
